Quest Diagnostics (DGX)
Quest Diagnostics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, federal contracts, earnings dates and insider trades. Listed on NYSE, classified by the SEC as services-medical laboratories.
3.4M
Short interest
settlement 2026-09-30
2.7
Days to cover
-1.0 days vs prior
61.2%
Short share of volume
2026-10-09
13
Fails to deliver
settlement 2026-09-10
Tue 20 Oct
Next earnings
estimated date
-$8.3M
Insider flow, 90 days
0 buys, 5 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in DGX is 3,417,577 shares, down 27,984 shares over the last month. Over the last 48 readings it ranged from 1,909,937 shares (13 December 2024) to 5,848,033 shares (31 December 2025). At the reported average volume of 1.3M shares a day that is 2.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/dgx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 3,417,577 | -5.1% | 1,268,667 | 2.69 |
| 2026-09-15 | 3,600,559 | +4.5% | 975,562 | 3.69 |
| 2026-08-31 | 3,445,561 | +3.7% | 893,699 | 3.86 |
| 2026-08-14 | 3,321,414 | -9.8% | 711,512 | 4.67 |
| 2026-07-31 | 3,684,192 | +5.0% | 1,344,732 | 2.74 |
| 2026-07-15 | 3,509,407 | -6.0% | 823,847 | 4.26 |
| 2026-06-30 | 3,732,507 | +9.2% | 971,160 | 3.84 |
| 2026-06-15 | 3,419,621 | -0.3% | 802,904 | 4.26 |
| 2026-05-29 | 3,430,849 | -7.7% | 822,173 | 4.17 |
| 2026-05-15 | 3,715,019 | +9.6% | 744,798 | 4.99 |
| 2026-04-30 | 3,389,572 | -4.6% | 1,310,134 | 2.59 |
| 2026-04-15 | 3,551,568 | -14.9% | 771,838 | 4.60 |
| 2026-03-31 | 4,174,813 | +7.8% | 936,713 | 4.46 |
| 2026-03-13 | 3,871,587 | -0.0% | 744,853 | 5.20 |
| 2026-02-27 | 3,872,414 | -18.8% | 845,183 | 4.58 |
| 2026-02-13 | 4,771,280 | -18.1% | 1,457,533 | 3.27 |
| 2026-01-30 | 5,823,118 | +1.8% | 1,034,647 | 5.63 |
| 2026-01-15 | 5,719,590 | -2.2% | 968,665 | 5.90 |
| 2025-12-31 | 5,848,033 | +38.4% | 873,850 | 6.69 |
| 2025-12-15 | 4,225,484 | -1.7% | 988,052 | 4.28 |
| 2025-11-28 | 4,299,681 | +0.1% | 1,216,187 | 3.54 |
| 2025-11-14 | 4,294,155 | -6.9% | 1,110,077 | 3.87 |
| 2025-10-31 | 4,614,227 | +16.8% | 1,320,509 | 3.49 |
| 2025-10-15 | 3,949,817 | -8.8% | 980,235 | 4.03 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of DGX volume is 61.2%, up 26.1 points over the last five sessions. Over the last 30 readings it ranged from 35.1% (2 October 2026) to 90.8% (18 September 2026). The latest reading is in line with the 30-session average of 61.0%, on 261K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 160K | 261K | 61.2% | 0 |
| 2026-10-08 | 227K | 335K | 67.9% | 3 |
| 2026-10-07 | 211K | 310K | 68.0% | 0 |
| 2026-10-06 | 292K | 709K | 41.1% | 600 |
| 2026-10-05 | 252K | 386K | 65.3% | 3 |
| 2026-10-02 | 152K | 434K | 35.1% | 736 |
| 2026-10-01 | 171K | 421K | 40.6% | 65 |
| 2026-09-30 | 232K | 438K | 53.1% | 2,119 |
| 2026-09-29 | 265K | 616K | 43.1% | 2,770 |
| 2026-09-28 | 167K | 399K | 41.8% | 0 |
| 2026-09-25 | 215K | 330K | 65.1% | 0 |
| 2026-09-24 | 273K | 446K | 61.3% | 80 |
| 2026-09-23 | 263K | 459K | 57.3% | 310 |
| 2026-09-22 | 526K | 1.3M | 41.1% | 34 |
| 2026-09-21 | 258K | 320K | 80.7% | 22 |
| 2026-09-18 | 385K | 423K | 90.8% | 7,149 |
| 2026-09-17 | 302K | 381K | 79.1% | 1 |
| 2026-09-16 | 321K | 382K | 84.0% | 514 |
| 2026-09-15 | 459K | 686K | 66.9% | 3 |
| 2026-09-14 | 307K | 437K | 70.3% | 0 |
| 2026-09-11 | 260K | 439K | 59.3% | 2,694 |
| 2026-09-10 | 342K | 538K | 63.6% | 5 |
| 2026-09-09 | 172K | 287K | 60.0% | 0 |
| 2026-09-08 | 157K | 286K | 55.0% | 484 |
| 2026-09-04 | 199K | 285K | 70.0% | 0 |
| 2026-09-03 | 217K | 337K | 64.4% | 27 |
| 2026-09-02 | 254K | 473K | 53.7% | 50 |
| 2026-09-01 | 233K | 359K | 64.9% | 0 |
| 2026-08-31 | 188K | 307K | 61.4% | 1,314 |
| 2026-08-28 | 128K | 200K | 63.9% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 10 September 2026, the fails-to-deliver balance in DGX is 13 shares, down 15 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (7 August 2026) to 23,804 shares (29 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-10 | 13 | $235.46 | $3K |
| 2026-08-28 | 28 | $244.61 | $7K |
| 2026-08-25 | 53 | $243.87 | $13K |
| 2026-08-24 | 191 | $244.39 | $47K |
| 2026-08-20 | 2,302 | $241.76 | $557K |
| 2026-08-18 | 754 | $235.52 | $178K |
| 2026-08-07 | 1 | $238.50 | $239 |
| 2026-08-03 | 2,118 | $233.01 | $494K |
| 2026-07-29 | 20 | $235.94 | $5K |
| 2026-07-08 | 6,909 | $212.38 | $1.5M |
| 2026-07-02 | 83 | $216.02 | $18K |
| 2026-07-01 | 233 | $211.95 | $49K |
| 2026-06-30 | 5,459 | $212.64 | $1.2M |
| 2026-06-29 | 201 | $209.88 | $42K |
| 2026-06-24 | 6 | $197.18 | $1K |
| 2026-06-23 | 1,541 | $193.58 | $298K |
| 2026-06-22 | 1,541 | $195.00 | $300K |
| 2026-06-03 | 6,855 | $193.16 | $1.3M |
| 2026-06-02 | 8,172 | $192.20 | $1.6M |
| 2026-06-01 | 4,500 | $194.90 | $877K |
| 2026-05-29 | 23,804 | $196.20 | $4.7M |
| 2026-05-15 | 1,590 | $187.94 | $299K |
| 2026-05-08 | 2,927 | $190.84 | $559K |
| 2026-04-29 | 537 | $195.05 | $105K |
| 2026-04-28 | 31 | $196.63 | $6K |
| 2026-04-15 | 3 | $194.16 | $582 |
| 2026-04-02 | 47 | $197.69 | $9K |
| 2026-03-26 | 2,598 | $196.46 | $510K |
| 2026-03-25 | 11 | $196.08 | $2K |
| 2026-03-23 | 16,937 | $195.26 | $3.3M |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at DGX reported 5 open-market sells worth $8.3M in the last 90 days and no open-market buys. Latest filing: Davis J. E. (CEO and President) on 2026-09-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | Davis J. E. | CEO and President | Sell | 10K | $242.72 | $2.4M | 122K |
| 2026-08-28 | PREVOZNIK MICHAEL E | SVP & General Counsel | Gift | 1K | $0.00 | $0 | 37K |
| 2026-08-28 | PREVOZNIK MICHAEL E | SVP & General Counsel | Sell | 430 | $244.51 | $105K | 38K |
| 2026-08-28 | PREVOZNIK MICHAEL E | SVP & General Counsel | Sell | 6K | $243.63 | $1.5M | 38K |
| 2026-08-28 | PREVOZNIK MICHAEL E | SVP & General Counsel | Sell | 16K | $242.88 | $3.9M | 44K |
| 2026-08-28 | PREVOZNIK MICHAEL E | SVP & General Counsel | Option exercise | 23K | $112.17 | $2.5M | 60K |
| 2026-07-28 | DELANEY MARK E | SVP & Chief Commercial Officer | Sell | 2K | $235.18 | $376K | 10K |
| 2026-07-22 | SAMAD SAM | Executive Vice President & CFO | Grant | 102 | $206.81 | $21K | 33K |
| 2026-07-22 | Plewman Patrick | SVP for Diagnostic Services | L | 46 | $206.81 | $10K | 15K |
| 2026-07-22 | MAIN TIMOTHY L | Director | L | 21 | $206.81 | $4K | 22K |
| 2026-07-22 | Lassiter Wright III | Director | L | 6 | $206.81 | $1K | 10K |
| 2026-07-22 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L | 37 | $206.81 | $8K | 14K |
| 2026-07-22 | Gregg Vicky B | Director | Grant | 72 | $206.81 | $15K | 18K |
| 2026-07-22 | DELANEY MARK E | SVP & Chief Commercial Officer | L | 34 | $206.81 | $7K | 12K |
| 2026-07-22 | CARTER ROBERT B | Director | L | 11 | $206.80 | $2K | 4K |
| 2026-06-04 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Sell | 8K | $200.00 | $1.6M | 14K |
| 2026-06-04 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Option exercise | 5K | $121.81 | $588K | 22K |
| 2026-06-04 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Option exercise | 3K | $127.72 | $424K | 17K |
| 2026-06-01 | Davis J. E. | CEO and President | Sell | 10K | $194.14 | $1.9M | 132K |
| 2026-05-20 | WENTWORTH TIMOTHY C | Director | Grant | 1K | $0.00 | $0 | 1K |
| 2026-05-20 | RING TIMOTHY M | Director | Grant | 1K | $0.00 | $0 | 31K |
| 2026-05-20 | PFEIFFER GARY M | Director | Grant | 1K | $0.00 | $0 | 31K |
| 2026-05-20 | MORRISON DENISE M | Director | Grant | 1K | $0.00 | $0 | 12K |
| 2026-05-20 | MAIN TIMOTHY L | Director | Grant | 1K | $0.00 | $0 | 27K |
| 2026-05-20 | Lassiter Wright III | Director | Grant | 1K | $0.00 | $0 | 10K |
| 2026-05-20 | Gregg Vicky B | Director | Grant | 1K | $0.00 | $0 | 18K |
| 2026-05-20 | Doi Tracey | Director | Grant | 1K | $0.00 | $0 | 8K |
| 2026-05-20 | Diaz Luis | Director | Grant | 1K | $0.00 | $0 | 5K |
| 2026-05-20 | CARTER ROBERT B | Director | Grant | 1K | $0.00 | $0 | 4K |
| 2026-04-20 | SAMAD SAM | Executive Vice President & CFO | Grant | 108 | $194.70 | $21K | 33K |
| 2026-04-20 | Plewman Patrick | SVP for Diagnostic Services | L | 49 | $194.70 | $10K | 15K |
| 2026-04-20 | Lassiter Wright III | Director | L | 6 | $194.70 | $1K | 9K |
| 2026-04-20 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L | 39 | $194.70 | $8K | 13K |
| 2026-04-20 | Gregg Vicky B | Director | Grant | 68 | $194.70 | $13K | 17K |
| 2026-04-20 | DELANEY MARK E | SVP & Chief Commercial Officer | L | 37 | $194.70 | $7K | 12K |
| 2026-04-20 | CARTER ROBERT B | Director | L | 7 | $194.70 | $1K | 3K |
| 2026-03-09 | WENTWORTH TIMOTHY C | Director | Grant | 215 | $0.00 | $0 | 215 |
| 2026-03-05 | Plewman Patrick | SVP for Diagnostic Services | Sell | 3K | $206.21 | $589K | 15K |
| 2026-03-05 | PREVOZNIK MICHAEL E | SVP & General Counsel | Sell | 4K | $206.21 | $800K | 38K |
| 2026-03-05 | Doherty Catherine T. | EVP, Regional Businesses | Sell | 6K | $206.21 | $1.1M | 67K |
| 2026-03-04 | SAMAD SAM | Executive Vice President & CFO | Tax withholding | 8K | $204.86 | $1.6M | 33K |
| 2026-03-04 | SAMAD SAM | Executive Vice President & CFO | Grant | 14K | $204.86 | $2.9M | 41K |
| 2026-03-04 | Plewman Patrick | SVP for Diagnostic Services | Tax withholding | 3K | $204.86 | $579K | 18K |
| 2026-03-04 | Plewman Patrick | SVP for Diagnostic Services | Grant | 6K | $204.86 | $1.2M | 21K |
| 2026-03-04 | PREVOZNIK MICHAEL E | SVP & General Counsel | Tax withholding | 3K | $204.86 | $687K | 41K |
| 2026-03-04 | PREVOZNIK MICHAEL E | SVP & General Counsel | Grant | 7K | $204.86 | $1.5M | 45K |
| 2026-03-04 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Sell | 3K | $204.86 | $538K | 13K |
| 2026-03-04 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Grant | 6K | $204.86 | $1.3M | 16K |
| 2026-03-04 | Doherty Catherine T. | EVP, Regional Businesses | Tax withholding | 6K | $204.86 | $1.2M | 73K |
| 2026-03-04 | Doherty Catherine T. | EVP, Regional Businesses | Grant | 11K | $204.86 | $2.3M | 78K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON23 Form 144 notices on file for DGX worth $36.7M at the prices reported; 3 in the last 90 days worth $8.3M. Latest: Davis J. E. filed on 2026-09-01 to sell 10,000 shares ($2.4M) from 2026-09-01.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-01 | Davis J. E.Officer, Director | 10K | $2.4M | 0.009% | 2026-09-01 | Fidelity Brokerage Services LLC |
| 2026-08-28 | PREVOZNIK MICHAEL EOfficer | 23K | $5.5M | 0.021% | 2026-08-28 | Fidelity Brokerage Services LLC |
| 2026-07-28 | DELANEY MARK EOfficer | 2K | $376K | 0.001% | 2026-07-28 | Fidelity Brokerage Services LLC |
| 2026-06-04 | KUPPUSAMY KARTHIKOfficer | 8K | $1.6M | 0.007% | 2026-06-04 | Fidelity Brokerage Services LLC |
| 2026-06-01 | Davis J. E.Officer, Director | 10K | $1.9M | 0.009% | 2026-06-01 | Fidelity Brokerage Services LLC |
| 2026-03-05 | Plewman PatrickOfficer | 3K | $589K | 0.003% | 2026-03-05 | Fidelity Brokerage Services LLC |
| 2026-03-05 | PREVOZNIK MICHAEL EOfficer | 4K | $800K | 0.004% | 2026-03-05 | Fidelity Brokerage Services LLC |
| 2026-03-05 | Doherty Catherine T.Officer | 6K | $1.1M | 0.005% | 2026-03-05 | Fidelity Brokerage Services LLC |
| 2026-03-03 | Plewman PatrickOfficer | 410 | $85K | 0.000% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2026-03-03 | PREVOZNIK MICHAEL EOfficer | 526 | $109K | 0.000% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2026-03-03 | Doherty Catherine T.Officer | 632 | $131K | 0.001% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Davis J. E.Officer, Director | 10K | $2.1M | 0.009% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-02-19 | Plewman PatrickOfficer | 958 | $196K | 0.001% | 2026-02-19 | Fidelity Brokerage Services LLC |
| 2026-02-19 | PREVOZNIK MICHAEL EOfficer | 1K | $228K | 0.001% | 2026-02-19 | Fidelity Brokerage Services LLC |
| 2026-02-19 | Doherty Catherine T.Officer | 1K | $294K | 0.001% | 2026-02-19 | Fidelity Brokerage Services LLC |
| 2026-02-10 | Plewman PatrickOfficer | 6K | $1.2M | 0.005% | 2026-02-10 | Fidelity Brokerage Services LLC |
| 2025-11-25 | Gregg Vicky BDirector | 1K | $240K | 0.001% | 2025-11-25 | Fidelity Brokerage Services LLC |
| 2025-11-25 | Davis J. E.Officer, Director | 55K | $10.6M | 0.050% | 2025-11-25 | Fidelity Brokerage Services LLC |
| 2025-11-18 | DELANEY MARK EOfficer | 8K | $1.5M | 0.007% | 2025-11-18 | Fidelity Brokerage Services LLC |
| 2025-10-22 | PFEIFFER GARY MDirector | 1K | $270K | 0.001% | 2025-10-22 | Fidelity Brokerage Services LLC |
| 2025-09-26 | PREVOZNIK MICHAEL EOfficer | 227 | $43K | 0.000% | 2025-09-26 | Fidelity Brokerage Services LLC |
| 2025-09-24 | PREVOZNIK MICHAEL EOfficer | 175 | $33K | 0.000% | 2025-09-24 | Fidelity Brokerage Services LLC |
| 2025-09-23 | PREVOZNIK MICHAEL EOfficer | 28K | $5.3M | 0.025% | 2025-09-23 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of DGX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Capital Management at 7.5% of the class (8,274,567 shares), filed 2026-04-30 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 2 | T. Rowe Price Associates, Inc.investment adviser | 5.4M | 4.9% | 2026-06-30 |
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 8.3M | 7.5% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Portfolio Managementinvestment adviser | 6.1M | 5.5% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 13 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding DGX at their latest 13F. JSON6 of the 30 tracked managers held DGX at their latest 13F, $50.4M in total at quarter-end prices. Citadel Advisors is the largest at $28.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 133K | $28.2M | 0.00% | -214K |
| AQR Capital Management | 2026-06-30 | 61K | $12.9M | 0.00% | +11K |
| Point72 Asset Management | 2026-06-30 | 23K | $5.0M | 0.01% | new |
| Millennium Management | 2026-06-30 | 11K | $2.4M | 0.00% | -39K |
| D. E. Shaw & Co. | 2026-06-30 | 5K | $1.0M | 0.00% | -143K |
| Bridgewater Associates | 2026-06-30 | 4K | $796K | 0.00% | +285 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Quest Diagnostics reported revenue of $3.04B, up 10.2% from the same quarter a year earlier, and net income of $320.0M (2.84 diluted EPS). In FY 2025 it generated $1.89B of operating cash flow and spent $450.0M on buybacks and $353.0M on dividends. As of 2026-06-30, cash was $626.0M against $5.64B of debt.
- Cash
- $626.0M
- Debt
- $5.64B
- Equity
- $7.52B
- Total assets
- $16.94B
- Shares outstanding
- 110,373,360
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $3.04B | $320.0M | 10.5% | 2.84 |
| Q1 FY 2026 | 2026-03-31 | $2.90B | $252.0M | 8.7% | 2.24 |
| Q4 FY 2025derived | 2025-12-31 | $2.81B | $245.0M | 8.7% | n/a |
| Q3 FY 2025 | 2025-09-30 | $2.82B | $245.0M | 8.7% | 2.16 |
| Q2 FY 2025 | 2025-06-30 | $2.76B | $282.0M | 10.2% | 2.47 |
| Q1 FY 2025 | 2025-03-31 | $2.65B | $220.0M | 8.3% | 1.94 |
| Q4 FY 2024derived | 2024-12-31 | $2.62B | $222.0M | 8.5% | n/a |
| Q3 FY 2024 | 2024-09-30 | $2.49B | $226.0M | 9.1% | 1.99 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $11.04B | $992.0M | $1.89B | $527.0M | $450.0M | $353.0M |
| FY 2024 | 2024-12-31 | $9.87B | $871.0M | $1.33B | $425.0M | $151.0M | $331.0M |
| FY 2023 | 2023-12-31 | $9.25B | $854.0M | $1.27B | $408.0M | $275.0M | $314.0M |
| FY 2022 | 2022-12-31 | $9.88B | $946.0M | $1.72B | $404.0M | $1.41B | $305.0M |
| FY 2021 | 2021-12-31 | $10.79B | $2.00B | $2.23B | $403.0M | $2.20B | $309.0M |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-15 from the cover page.
Federal contracts
The largest contract actions for Quest Diagnostics and its subsidiaries. JSON29 contract actions on file for DGX: $40.6M obligated in the last 90 days and $46.5M in the last 12 months across 3 awarding agencies. The largest was $7.2M from the Department of Veterans Affairs on 2026-10-01 (fy27 task order - 10/1/2026 - 6/30/2027). This covers the largest contract actions, not every award, and agencies report late.
| Action date | Agency | Amount | Type | Description |
|---|---|---|---|---|
| 2026-10-08 | Department of Veterans AffairsDepartment of Veterans Affairs | $25K | mod P00002definitive contract | MOBILE VITALS & SPECIMEN COLLECTION, EXERCISE OPTION 1USAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $7.2M | new awarddelivery order | FY27 TASK ORDER - 10/1/2026 - 6/30/2027USAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $3.1M | new awarddelivery order | VISN 12 MULTI-SITE REFERENCE LABORATORY TESTING SERVICES FY27 TOUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $2.7M | new awarddelivery order | REFERENCE LAB TESTS ORLANDO VAMCUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $2.7M | new awarddelivery order | LAB REFERENCE TESTING VAMHCSUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $2.2M | new awarddelivery order | LAB REFERENCE TESTING MARTINSBURG VAMCUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $2.1M | new awarddelivery order | REFERENCE LAB TESTSUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $2.0M | new awarddelivery order | REFERENCE LAB TESTSUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.9M | new awarddelivery order | LAB REFERENCE TESTING DC VAMCUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.6M | new awarddelivery order | REFERENCE LAB TESTSUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.6M | mod P00007purchase order | PRIMARY REFERENCE LABORATORY TESTING / COURIER SERVICES / PHLEBOTOMYUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.5M | new awarddelivery order | REFERENCE LAB TESTSUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.5M | new awarddelivery order | REFERENCE LABORATORYUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.4M | new awarddelivery order | REFERENCE LABORATORYUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.4M | new awardbpa call | REFERENCE LAB SERVICES EO 14398 REQUIREMENT.USAspending |
| 2026-09-29 | Department of Veterans AffairsDepartment of Veterans Affairs | $3.5M | new awarddelivery order | QUEST DIAGNOSTICS - HEMATOLOGY MOLECULAR TESTING SERVICESUSAspending |
| 2026-09-15 | Department of Health and Human ServicesCenters for Disease Control and Prevention | $610K | mod P00001delivery order | TEST SURGE AND DATA SHARING MULTIPLE AWARD INDEFINITE DELIVERY INDEFINITE QUANTITY (IDIQ)USAspending |
| 2026-08-25 | Department of Veterans AffairsDepartment of Veterans Affairs | $524K | mod P00001bpa call | VISN 6 REFERENCE LAB TESTING AND COURIER SERVICES - ADD COURIER SERVICES.USAspending |
| 2026-08-21 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.9M | mod P00001purchase order | OPTION PERIODUSAspending |
| 2026-08-21 | Department of Health and Human ServicesCenters for Disease Control and Prevention | $625K | mod P00002delivery order | EO 14398USAspending |
| 2026-08-09 | Department of Veterans AffairsDepartment of Veterans Affairs | $150K | mod P00002bpa call | VISN 6 REFERENCE LAB TESTING AND COURIER SERVICES - OY3 CORRECT ERROR IN FUNDINGUSAspending |
| 2026-07-31 | Department of Veterans AffairsDepartment of Veterans Affairs | $507K | mod P00001delivery order | REFERENCE LABORATORY SERVICESUSAspending |
| 2026-07-07 | Department of Health and Human ServicesCenters for Disease Control and Prevention | $1.1M | mod P00003delivery order | TEST SURGE AND DATA SHARING MULTIPLE AWARD INDEFINITE DELIVERY INDEFINITE QUANTITY (IDIQ)USAspending |
| 2026-07-07 | Department of the InteriorDepartmental Offices | $341K | mod P00001delivery order | HRD-26-061 QUEST 4/1/26-3/31/27USAspending |
| 2026-06-30 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.0M | new awarddelivery order | TASK ORDER FOR REFERENCE LAB TESTING SERVICES VISN 12 MULTI-SITE 7/1/2026 - 9/30/2026USAspending |
| 2026-06-29 | Department of Veterans AffairsDepartment of Veterans Affairs | $895K | mod P00001delivery order | LAB TESTING FOR PATIENTSUSAspending |
| 2026-06-26 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.6M | mod P00005purchase order | PRIMARY REFERENCE LABORATORY TESTING / COURIER SERVICES / PHLEBOTOMYUSAspending |
| 2026-06-26 | Department of Veterans AffairsDepartment of Veterans Affairs | $675K | new awardbpa call | URGENT BRIDGE SPECIALIZED GENETIC AND ESOTERIC LAB TESTING VISN 2 DOWNSTATEUSAspending |
| 2026-06-22 | Department of Veterans AffairsDepartment of Veterans Affairs | $222K | mod P00001delivery order | REFERENCE LAB TESTING - MODIFICATION TO INCREASE FUNDINGUSAspending |
What this page is
Quest Diagnostics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Quest Diagnostics (DGX), SEC CIK 1022079, listed on NYSE, classified by the SEC as services-medical laboratories. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-10.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-01.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Federal contracts
- USAspending.govSource: USAspending.gov.The largest contract actions each day, as agencies report them (up to 90 days late). Latest 2026-10-08.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-23.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1022079Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as services-medical laboratories
Other company pages
Datasets
Frequently Asked Questions
How much of DGX is sold short?
3,417,577 shares were held short at the 2026-09-30 settlement, 2.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is DGX's daily short volume?
On 2026-10-09, 159,636 of the 260,711 DGX shares reported to FINRA were sold short, 61.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does DGX have fails to deliver?
The SEC's latest file shows 13 DGX shares failed to deliver at settlement 2026-09-10. Fails are reported per settlement date and published twice a month with a lag.
Are DGX insiders buying or selling?
Insiders at DGX reported 5 open-market sells worth $8.3M in the last 90 days and no open-market buys. Latest filing: Davis J. E. (CEO and President) on 2026-09-01.
Have DGX insiders filed to sell?
23 Form 144 notices on file for DGX worth $36.7M at the prices reported; 3 in the last 90 days worth $8.3M. Latest: Davis J. E. filed on 2026-09-01 to sell 10,000 shares ($2.4M) from 2026-09-01.
Who owns 5% or more of DGX?
2 holders report 5% or more of DGX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Capital Management at 7.5% of the class (8,274,567 shares), filed 2026-04-30 for an event on 2026-03-31.
What did DGX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Quest Diagnostics reported revenue of $3.04B, up 10.2% from the same quarter a year earlier, and net income of $320.0M (2.84 diluted EPS). In FY 2025 it generated $1.89B of operating cash flow and spent $450.0M on buybacks and $353.0M on dividends. As of 2026-06-30, cash was $626.0M against $5.64B of debt.
Which tracked 13F managers own DGX?
6 of the 30 tracked 13F managers held DGX shares at their latest filing, $50.4M in all. The largest: Ken Griffin's Citadel Advisors (133K shares, $28.2M), Cliff Asness's AQR Capital Management (61K shares, $12.9M), Steve Cohen's Point72 Asset Management (23K shares, $5.0M), Izzy Englander's Millennium Management (11K shares, $2.4M), D. E. Shaw & Co. (5K shares, $1.0M), Ray Dalio's Bridgewater Associates (4K shares, $796K).
How much federal contract money did DGX receive?
$40.6M was obligated to Quest Diagnostics and its subsidiaries in the last 90 days and $46.5M in the last 12 months, counting the largest contract actions on USAspending, not every award. Obligations are not revenue; they are spent over each contract's life.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.